Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Using Multi-omics

NCT07263373 | Completed

• 1 other identifier: 2025-SR-695
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Bronchiectasis is a heterogeneous condition with diverse etiologies and clinical manifestations. Its progression involves a vicious cycle of airway inflammation, recurrent infection, and structural damage, leading to persistent symptoms and declining lung function. Current management focuses on airway clearance and antibiotics, with no disease-modifying therapies available. Recognizing this heterogeneity is crucial for advancing targeted treatments and precision medicine. Radiomics converts medical images into mineable data to reveal underlying pathophysiology. While applied in other respiratory diseases, its potential in bronchiectasis remains underexplored. Both radiomics and the lung microbiome are independently linked to disease severity in conditions like COPD, but their interplay is unclear. Integrating these modalities with clinical data could unlock novel insights, identify new therapeutic targets, and improve diagnostic and prognostic models. However, few studies have investigated multimodal models combining radiomics, microbiome, and clinical features to predict outcomes in bronchiectasis. To address this gap, we designed a multicenter, retrospective study. It will analyze data from patients diagnosed between January 2020 and July 2025 to evaluate the combined value of radiomics, microbial features, and clinical parameters in diagnosing and predicting the progression of bronchiectasis.

Conditions

Bronchiectasis Adult; Radiomics

Outcome Measures

Primary Outcomes (1)

• death

  2025.7

Study Arms (1)

Bronchiectasis

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with a diagnosis of bronchiectasis established by high-resolution CT (HRCT) of the chest and its corresponding radiology report.

You may qualify if:

• ① Diagnosis of bronchiectasis;
• Availability of both raw high-resolution computed tomography (HRCT) chest images and the corresponding radiology report; ③ Age ≥ 18 years.

You may not qualify if:

• ① Incomplete clinical data;
• Absence of chest CT imaging studies and reports; ③ Other patients deemed ineligible for enrollment at the investigator's discretion.

Sponsors & Collaborators

• The First Affiliated Hospital with Nanjing Medical University: lead

Study Sites (1)

The First Affiliated Hospital of Nanjing Medical University，

Nanjing, Jiangsu, 21000, China

Location

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 24, 2025
• First Posted: December 4, 2025
• Study Start: January 1, 2020
• Primary Completion: June 30, 2025
• Study Completion: July 31, 2025
• Last Updated: December 4, 2025

Record last verified: 2025-11

Locations

CN (1)